Abstract
Studies investigating behavior in mice with a heterozygous null mutation of the NF1 gene (Nf1 +/−) have provided critical insights into the molecular and cellular mechanisms underlying cognitive impairments associated with neurofibromatosis type 1 (NF1). Hyperactivation of the Ras-MAPK signaling cascade, which results in increased GABA-mediated inhibition and significantly reduced long-term potentiation, has been proposed as a core mechanism underlying Nf1 +/− mice deficits in visuospatial learning and attention. This assertion has been reinforced by preclinical trials that reveal that these impairments can be rescued both at a cognitive and cellular level. We attempted to demonstrate a phenotypic parallel between Nf1 +/− mice and children with NF1 using a well-validated measure of visuospatial learning. Children with NF1 (n = 71) and healthy controls (n = 29) were assessed on a computerized paired associate learning task. Interrelationships between visuospatial learning and other cognitive abilities that may influence performance, such as intelligence, attention and visuospatial function, were explored. Children with NF1 displayed significant impairments in visuospatial learning, with reduced initial retention and poorer learning across repeated trials. Importantly, we demonstrated that visuospatial learning was inferior in NF1 even after accounting for group differences in intelligence, sustained attention and visuospatial abilities. We have thus identified impaired visuospatial learning as a core phenotypic feature in children with NF1. These findings imply that hippocampal-based learning networks are dysfunctional in children with NF1 and provide validation for a primary outcome measure for clinical trials aiming to correct aberrant Ras signaling.
Similar content being viewed by others
References
Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2000) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet 152A:327–332
Hyman SL, Shores EA, North KN (2005) The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037–1044
Moore BD III, Ater JL, Needle MN, Slopis J, Copeland DR (1994) Neuropsychological profile of children with neurofibromatosis, brain tumor, or both. J Child Neurol 9:368–377
Rowbotham I, Pit-ten Cate IM, Sonuga-Barke EJ, Huijbregts SC (2009) Cognitive control in adolescents with neurofibromatosis type 1. Neuropsychology 23:50–60
Levine TM, Materek A, Abel J, O’Donnell M, Cutting LE (2006) Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol 13:8–20
Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15:1961–1967
Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ (2008) Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135:549–560
Squire LR (1992) Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol Rev 99:195–231
Levy DA, Bayley PJ, Squire LR (2004) The anatomy of semantic knowledge: medial vs. lateral temporal lobe. Proc Natl Acad Sci USA 101:6710–6715
Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ (1997) Computerized neuropsychological tests in the early detection of dementia: prospective findings. J Int Neuropsychol Soc 3:139–146
Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ (2002) Paired associate performance in the early detection fo DAT. J Int Neuropsychol Soc 8:58–71
Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW (1995) Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 33:1–24
Taffe MA, Weed MR, Gutierrez T, Davis SA, Gold LH (2002) Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys. Psychopharmacology 160:253–262
Nicoll RA, Malenka RC (1999) Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann N Y Acad Sci 868:515–525
National Institutes of Health Consensus Development Statement (1988) Neurofibromatosis. Arch Neurol 45:575–578
Conners CK (1997) Conners’ rating scales-revised. Multi-Health Systems Inc., New York
Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, Robbins TW (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson’s disease. Brain 111:695–718
Wechsler D (2003) Wechsler intelligence scales for children, 4th edn. The Psychological Corporation, San Antonio
Manly T, Robertson IH, Anderson V, Nimmo-Smith I (1999) The test of everyday attention for children. Battley Brothers, London
Benton AL, Varney NR, Hamsher K (1976) Judgment of line orientation. Department of Neurology, University of Iowa, Iowa City
Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70
Tabachnick BG, Fidell LS (2007) Using mulivariate statistics, 5th edn. Allyn and Bacon, Boston
Singer JJ, MacGregor AJ, Cherkas LF, Spector TD (2006) Genetic influences on cognitive function using the Cambridge Neuropsychological Test Automated Battery. Intelligence 34:421–428
Hofman KJ, Harris EL, Bryan RN, Denckla MB (1994) Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 124:S1–S8
Ullrich NJ, Ayr L, Leaffer E, Irons MB, Rey-Casserly C (2010) Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1. J Child Neurol 25:1195–1202
Moore BD III, Slopis JM, Schomer D, Jackson EF (2000) Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology 46:1660–1668
Payne JM, Moharir MD, Webster R, North KN (2010) Brain structure and function in neurofibromatosis type 1: current concepts and future directions. J Neurol Neurosurg Psychiatry 81:304–309
Pride N, Payne JM, Webster R, Shores EA, Rae C, North KN (2010) Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol 25:834–841
Hancock JF (2003) Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 4:373–384
Shilyansky C, Lee YS, Silva AJ (2010) Molecular and cellular mechanisms of learning disabilities: a focus on NF1. Annu Rev Neurosci 33:221–243
Cooke SF, Bliss TV (2006) Plasticity in the human central nervous system. Brain 129:1659–1673
Neves G, Cooke SF, Bliss TV (2008) Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nat Rev Neurosci 9:65–75
Fray PJ, Robbins TW, Sahakian BJ (1996) Neuorpsychiatyric applications of CANTAB. Int J Geriatr Psychiatry 11:329–336
Von Huben SN, Davis SA, Lay CC, Katner SN, Crean RD, Taffe MA (2006) Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys. Psychopharmacology 188:586–596
Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR (2004) Detecting dementia: novel neuropsychological markers of preclinical Alzheimer’s disease. Dement Geriatr Cogn Disord 17:42–48
Nestor PJ, Scheltens P, Hodges JR (2004) Advances in the early detection of Alzheimer’s disease. Nat Med 10:S34–S41
Lowe C, Rabbitt P (1998) Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia 36:915–923
Acosta MT, Kardel PG, Walsh KS, Rosenbaum KN, Gioia GA, Packer RJ (2011) Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol 45:241–245
Dennis M, Francis DJ, Cirino PT, Schachar R, Barnes MA, Fletcher JM (2009) Why IQ is not a covariate in cognitive studies of neurodevelopmental disorders. J Int Neuropsychol Soc 15:331–343
Cutting LE, Koth CW, Denckla MB (2000) How children with neurofibromatosis type 1 differ from “typical” learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 17:29–47
Acknowledgments
This study was funded by the Sherman Fellowship in Neurofibromatosis 1 Research Australia, awarded to Dr. Payne.
Conflicts of interest
The authors declare that they have no conflict of interest.
Ethical standard
This research has been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Payne, J.M., Barton, B., Shores, E.A. et al. Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials. J Neurol 260, 214–220 (2013). https://doi.org/10.1007/s00415-012-6620-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-012-6620-5